DNLI Stock Overview
A biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Denali Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.45 |
| 52 Week High | US$33.33 |
| 52 Week Low | US$14.56 |
| Beta | 1.35 |
| 1 Month Change | -13.12% |
| 3 Month Change | -29.07% |
| 1 Year Change | -2.32% |
| 3 Year Change | -54.79% |
| 5 Year Change | 17.34% |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
Dec 09
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Aug 20Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Jul 26Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
May 23Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Apr 17Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Mar 21Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Mar 07Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Feb 21Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Jan 26We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Nov 20Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking
Oct 09Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Aug 22Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price
May 02Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be
Mar 04Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation
Feb 06These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat
Nov 09Denali Therapeutics proposes $250M stock offering; shares down 6% post market
Oct 18Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Oct 12Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122
Oct 10We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Jun 08Shareholder Returns
| DNLI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.6% | -3.6% | -2.4% |
| 1Y | -2.3% | -2.6% | 23.4% |
Return vs Industry: DNLI matched the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: DNLI underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| DNLI volatility | |
|---|---|
| DNLI Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DNLI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DNLI's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 390 | Ryan Watts | www.denalitherapeutics.com |
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.
Denali Therapeutics Inc. Fundamentals Summary
| DNLI fundamental statistics | |
|---|---|
| Market cap | US$3.09b |
| Earnings (TTM) | -US$427.49m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.2x
P/E RatioIs DNLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNLI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$412.36m |
| Gross Profit | -US$412.36m |
| Other Expenses | US$15.14m |
| Earnings | -US$427.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DNLI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Denali Therapeutics Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Tazeen Ahmad | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |